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Abstract. 
Patients with advanced non-small cell lung cancer (NSCLC) are currently treated primar-
ily with chemotherapy. In 2011, almost 60% of newly diagnosed advanced NSCLC patients in 
Taiwan received chemotherapy. In these patients, chemotherapy increases survival rate and 
time and relieves some symptoms, but it also affects their physical and psychological func-
tioning, impacts on social interaction, causes economic burden, and decreases quality of life 
(QOL).  
We conducted a meta-analysis of the English and Chinese (both simplified and traditional) 
literature on the changes and determinants of QOL measured by the EORTC QLQ-C30 in ad-
vanced NSCLC patients undergoing chemotherapy. Results from our meta-analysis of 11 
studies identified from 5 databases indicated that overall QOL and physical function did not 
change significantly from pre-chemotherapy through cycles 1-6 of chemotherapy, but there 
were significant improvements in the domains of role, emotion, cognition, and social function.  
Our systematic review showed that better QOL was associated with younger age, better 
economic status, employment, religious beliefs, better performance status, low chemotherapy 
doses, better treatment responses, less frequent, severe, and distressing symptoms, less anxiety 
and depression, and stronger social support. QOL was not consistently associated with educa-
tional attainment, time since cancer diagnosis, and cancer stage. 
The findings of this meta-analysis and systematic review suggest that by appropriately 
managing high-risk NSCLC patients’ symptom distress, alleviating their anxiety and depres-
sive symptoms, and enhancing their social support, health care professionals can improve the 
QOL of advanced NSCLC patients undergoing chemotherapy. 
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合癌症網（National Comprehensive Cancer Network; 
NCCN）2014年治療指引顯示僅有罹患肺腺癌，且
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問卷（European Organization for the Research and 
Treatment of Cancer quality of life questionnaire；
EORTC QLQ-C30）進行生活品質評估，僅有少數
學者使用肺癌症狀量表（Lung Cancer Symptom 
Scale；LCSS）和肺癌治療功能性評估（Funtional 









































 化學治療前 第 1 個週期 第 2 個週期 第 3 個週期 第 4 個週期 第 5 個週期 第 6 個週期
生活品質 55.70±17.70 55.66±14.17 59.85±16.42 59.04±71.42 58.64±10.00  59.42±12.07
與基礎值差異  -0.04 4.15 3.34 2.94  3.72 
與前一測量點差異   4.19 -0.81 -0.40  0.78 
身體功能 67.13±41.83 78.57±17.76 67.09±19.25 60.91±86.06 74.46±26.32  79.13±15.34
與基礎值差異  11.44 -0.04 -6.22 7.33  12.00 
與前一測量點差異   -11.48 -6.18 13.55  4.67 
角色功能 61.94±46.55 63.59±25.20 63.59±29.36 54.46±26.98 71.52±44.03  74.40±61.09
與基礎值差異  1.65 1.65 -7.48 9.58  12.46* 
與前一測量點差異   0.00 -9.13 17.06*  2.88 
情緒功能 67.76±25.14 71.24±22.99 74.76±23.23 70.52±24.28 79.80±55.00  89.41±9.20
與基礎值差異  3.48 7.00* 2.76 12.04*  21.65* 
與前一測量點差異   3.52 -4.24 9.28*  9.61* 
認知功能 77.97±39.26 80.29±18.86 78.50±37.63 78.55±24.36 86.88±29.16  89.48±13.60
與基礎值差異  2.32 0.53 0.58 8.91*  11.51* 
與前一測量點差異   -1.79 0.05 8.33*  2.60 
社會功能 67.75±56.13 71.92±30.04 68.52±52.29 66.95±29.08 77.09±24.72  77.14±14.37
與基礎值差異  4.17 0.77 -0.80 9.34  9.39 
與前一測量點差異   -3.40 -1.57 10.14*  0.05 




















































































究合作組織 (Eastern Cooperative Oncology Group 
Performance Status；ECOG）所發展的量表進行身
體功能狀況評估，分數越高代表身體功能狀況越
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差，研究皆提出身體功能狀況與生活品質呈負相關
（r=-.23~-.63, p<.05）[7,29]，黃(2009) 亦報告身體
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